The Galapagos CFTR potentiator, GLPG2451, is an oral, once-daily clinical candidate for cystic fibrosis (5-80 mg QD). It was advanced into a high-profile Ph. II triple-combo study with the CFTR correctors GLPG2737 and GLPG2222 in partnership with AbbVie, and was seen as a potential competitor to Vertex’s CF franchise, but unfortunately weak [...]
< 1 minute read
Sep. 18, 2021
GLPG2451: An Oral CFTR ABC Transporter Potentiator
GLPG2451
oral CFTR ABC transporter potentiator Ph. II for cystic fibrosis (5-80 mg QD), discont. similarity screen of 589 cmpds + scaffold hop J. Med. Chem., Jan. 5, 2021 Galapagos NV, Mechelen, BE
Loading...
